Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.56 |
| ▸ | G6PD | P11413 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 4/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.46 |
| ▸ | MITF | O75030 | 1/20 | 0.46 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6496200 | 0.90 | MEN1 (0.55) | POLBG6PDHPGDALDH1A1MAPK1 | |
| Hydrochloric Acid SCHEMBL6491093 | 0.88 | MEN1 (0.54) | POLBG6PDHPGDALDH1A1MAPK1 | |
| SCHEMBL6491892 | 0.86 | ALDH1A1 (0.67) | POLBG6PDHPGDALDH1A1MAPK1 | |
| SCHEMBL2604927 | 0.85 | MAPT (0.61) | HPGDALDH1A1KDM4EMAPTLMNA | |
| SCHEMBL6498396 | 0.85 | MAPT (0.61) | HPGDALDH1A1KDM4EMAPTLMNA | |
| SCHEMBL29227193 | 0.84 | NPC1 (0.61) | POLBG6PDHPGDALDH1A1MAPK1 | |
| SCHEMBL29227201 | 0.84 | NPC1 (0.61) | POLBG6PDHPGDALDH1A1MAPK1 | |
| SCHEMBL6502160 | 0.83 | MEN1 (0.47) | POLBG6PDHPGDALDH1A1MAPK1 | |
| SCHEMBL29227102 | 0.80 | NPC1 (0.50) | POLBG6PDHPGDALDH1A1MAPK1 | |
| SCHEMBL29227096 | 0.80 | NPC1 (0.50) | POLBG6PDHPGDALDH1A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6846830-B2 | Naphtalene derivatives and their pharmaceutical use | ELI LILLY AND COMPANY (US) | 2005-01-25 | — | — | US | claimed |
| US-6846830-B2 | Naphtalene derivatives and their pharmaceutical use | ELI LILLY AND COMPANY (US) | 2005-01-25 | — | — | US | disclosed |
| US-20030073725-A1 | Naphtalene derivatives and their pharmaceutical use | ELI LILLY AND COMPANY | 2003-04-17 | — | — | US | disclosed |
| EP-1272469-A1 | NAPHTHALENE DERIVATIVES AND THEIR PHARMACEUTICAL USE | ELI LILLY AND COMPANY (US) | 2003-01-08 | — | — | EP | disclosed |
| EP-1138328-A1 | Naphthalene derivatives as CNS drugs | ELI LILLY AND COMPANY LIMITED (GB) | 2001-10-04 | — | — | EP | disclosed |
| WO-2001072709-A1 | NAPHTALENE DERIVATIVES AND THEIR PHARMACEUTICAL USE | ELI LILLY AND COMPANY (US) | 2001-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073725-A1 | Naphtalene derivatives and their pharmaceutical use | CHRNA6, ATP6V1B2, GRM6 | POLB 2825/4885G6PD 494/4885HPGD 1020/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.